Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics (CRSP) is a clinical-stage biopharmaceutical leader pioneering CRISPR/Cas9 gene editing therapies for serious diseases. This page aggregates official announcements, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and researchers will find timely updates on therapeutic programs targeting hemoglobinopathies, oncology, and autoimmune disorders. Track regulatory milestones, partnership announcements with industry leaders, and financial performance reports. All content is curated to meet investor needs for decision-making clarity.
Key updates include progress in allogeneic CAR-T cell therapies, hemoglobinopathy treatment approvals, and manufacturing scale-up initiatives. Bookmark this page for structured access to CRISPR Therapeutics' latest scientific advancements and business developments.
CRISPR Therapeutics announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 9:20 a.m. PT. Senior management members will present insights on the company's advancements in gene-based medicines for serious diseases, leveraging the CRISPR/Cas9 technology. A live webcast of the presentation will be accessible on their Investors page, with a replay available for 14 days post-event. CRISPR Therapeutics continues to develop therapies across various sectors, including oncology and rare diseases, collaborating with major partners like Bayer and Vertex Pharmaceuticals.
Vertex Pharmaceuticals and CRISPR Therapeutics announced additional abstracts for the 2022 European Hematology Association (EHA) Congress. The highlight is the late-breaking abstract on the efficacy and safety of exa-cel for beta-thalassemia and sickle cell disease, scheduled for oral presentation on June 12. Three real-world economics abstracts will also be presented on June 10, detailing the economic burden of these diseases in the U.S. Exa-cel is being investigated as a one-time therapy for these patients.
CRISPR Therapeutics (Nasdaq: CRSP) will host an Innovation Day on June 21, 2022, at 2:00 PM ET, focusing on its advanced research in genetic engineering and cell therapy. The event will showcase the company's innovative platform technologies and new discovery programs. A live webcast will be available on the company's website, with the recording archived for 30 days post-event. CRISPR Therapeutics is committed to developing transformative gene-based medicines targeting serious diseases, leveraging its proprietary CRISPR/Cas9 technology.
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Dr. Phuong Khanh (P.K.) Morrow as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings over a decade of experience in global drug development, particularly in oncology, and will oversee the company's clinical development and regulatory operations. The leadership change aims to enhance CRISPR’s innovative gene-editing therapies. CEO Samarth Kulkarni emphasized her expertise will be essential in advancing their clinical strategy and building the organization.
CRISPR Therapeutics (Nasdaq: CRSP) announced that an abstract detailing safety and efficacy data from the ongoing CTX130 clinical trial for T-cell lymphoma has been accepted for oral presentation at the EHA 2022 Hybrid Congress, taking place June 9-12, 2022. This marks the first presentation of clinical data from the CTX130 program. The abstract, titled The COBALT-LYM Study of CTX130, will be presented by Dr. Swaminathan P. Iyer on June 11, 2022. CTX130 is a gene-edited CAR-T therapy targeting CD70, being investigated in two Phase 1 trials for relapsed/refractory malignancies.
CRISPR Therapeutics (CRSP) reported Q1 2022 financial results, highlighting significant progress in clinical trials. Key milestones include dosing over 75 patients with CTX001 in ongoing Phase 3 trials for beta thalassemia and sickle cell disease, with global regulatory submissions anticipated in late 2022. R&D expenses rose to $118.2 million, reflecting ongoing advancements in its immuno-oncology pipeline. Cash reserves stood at $2.22 billion, down from $2.38 billion in Q4 2021. Net loss for the quarter was $179.2 million, compared to $113.2 million a year prior.
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management team will participate in the 2022 Bank of America Healthcare Conference on May 11, 2022, at 4:40 p.m. PT. A live webcast will be available on the Company's Investors section of the website, with a replay accessible for 14 days post-event. The company focuses on gene-based medicines to tackle serious diseases using its innovative CRISPR/Cas9 platform. CRISPR Therapeutics operates in multiple therapeutic areas, including oncology and rare diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) has announced the proposed election of Maria Fardis, Ph.D., MBA, to its Board of Directors at the upcoming annual general meeting. With a strong background in biopharmaceuticals, including her leadership at Iovance Biotherapeutics and Acerta Pharma, Dr. Fardis is expected to enhance the company's ability to advance its gene-based medicines pipeline. CEO Samarth Kulkarni highlighted her extensive experience as a valuable asset for CRISPR Therapeutics as it seeks to address serious medical conditions.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in three key investor conferences in April 2022. These include the 21st Annual Needham Virtual Healthcare Conference on April 12 at 12:45 PM ET, the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14 at 1:00 PM ET, and the 14th Kempen Life Sciences Conference in Amsterdam on April 20 at 3:30 PM CET. Live webcasts will be accessible on the company's website, with a 14-day replay available post-event.
CRISPR Therapeutics focuses on gene-based medicines for serious diseases using its innovative CRISPR/Cas9 technology.
CRISPR Therapeutics (Nasdaq: CRSP) will present an e-poster at the AACR 2022 Annual Meeting from April 8-13, 2022, highlighting its innovative cancer immunotherapy research. The presentation titled “CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells” is set for April 8, 2022. This research emphasizes the potential of CRISPR/Cas9 technology in advancing cancer treatments. As a leader in gene editing, CRISPR Therapeutics aims to develop transformative therapies for serious diseases, collaborating with major firms like Bayer and Vertex Pharmaceuticals.
